KR890011606A - 항응고제 - Google Patents

항응고제 Download PDF

Info

Publication number
KR890011606A
KR890011606A KR1019890000792A KR890000792A KR890011606A KR 890011606 A KR890011606 A KR 890011606A KR 1019890000792 A KR1019890000792 A KR 1019890000792A KR 890000792 A KR890000792 A KR 890000792A KR 890011606 A KR890011606 A KR 890011606A
Authority
KR
South Korea
Prior art keywords
anticoagulant
heparin
protein
activated protein
activity
Prior art date
Application number
KR1019890000792A
Other languages
English (en)
Other versions
KR0127754B1 (ko
Inventor
게이쪼 히라하라
Original Assignee
아다찌 카주오
훽스트 저팬 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11897770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR890011606(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아다찌 카주오, 훽스트 저팬 리미티드 filed Critical 아다찌 카주오
Publication of KR890011606A publication Critical patent/KR890011606A/ko
Application granted granted Critical
Publication of KR0127754B1 publication Critical patent/KR0127754B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Paper (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

항응고제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 단백질 C의 농도와 응고시간과의 상관 그래프이다.

Claims (3)

  1. 단백질 C또는 활성화된 단백질 C 및 헤파린을 함유하는 항응고제.
  2. 제1항에 있어서, 부가적으로 안티트롬빈 Ⅲ을 함유하는 항응고제.
  3. 응혈 장해 치료용 약제를 생성하기 위한 제1항 또는 2항에 따른 항응고제의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890000792A 1988-01-28 1989-01-26 항응고제 KR0127754B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP63-15761 1988-01-28
JP63015761A JP2739050B2 (ja) 1988-01-28 1988-01-28 抗血液凝固剤
JP?63-15761 1988-01-28

Publications (2)

Publication Number Publication Date
KR890011606A true KR890011606A (ko) 1989-08-21
KR0127754B1 KR0127754B1 (ko) 1998-04-01

Family

ID=11897770

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890000792A KR0127754B1 (ko) 1988-01-28 1989-01-26 항응고제

Country Status (13)

Country Link
US (1) US5084273A (ko)
EP (1) EP0326014B1 (ko)
JP (1) JP2739050B2 (ko)
KR (1) KR0127754B1 (ko)
AT (1) ATE74273T1 (ko)
AU (1) AU607303B2 (ko)
CA (1) CA1330299C (ko)
DE (1) DE68901098D1 (ko)
DK (1) DK37789A (ko)
ES (1) ES2039709T3 (ko)
GR (1) GR3005040T3 (ko)
IE (1) IE63528B1 (ko)
PT (1) PT89534B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8822147D0 (en) * 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
SE464135B (sv) * 1989-07-14 1991-03-11 Kabivitrum Ab Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
EP0651655A4 (en) 1992-07-24 1996-05-29 Oklahoma Med Res Found REDUCTION OF MICROVASCULAR BLEEDING DURING SURGERY BY BLOCKING PROTEIN C ACTIVATION
US5589516A (en) * 1993-04-05 1996-12-31 The Green Cross Corporation Liquid preparation of antithrombin-III and stabilizing method therefor
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5516889A (en) * 1993-06-21 1996-05-14 University Technologies International, Inc. Synthetic thrombin receptor peptides
WO1995030429A1 (en) * 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
JPH08224227A (ja) * 1995-02-22 1996-09-03 Internatl Reagents Corp 血液採血管
US6562781B1 (en) * 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6491965B1 (en) 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
IL132502A0 (en) * 1997-04-28 2001-03-19 Lilly Co Eli Improved methods for processing activated protein c
ID23908A (id) * 1997-06-05 2000-05-25 Lilly Co Eli Metode pengobatan dari penyakit trombosis
GB9711927D0 (en) * 1997-06-09 1997-08-06 Bristol Myers Squibb Co Compositions useful as fibrin sealants
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
JP2004511428A (ja) 2000-05-24 2004-04-15 イーライ・リリー・アンド・カンパニー 凝固亢進状態を処置するための製剤および方法
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
CA2475738A1 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
WO2009096445A1 (ja) * 2008-01-29 2009-08-06 Kyowa Hakko Kirin Co., Ltd. 神経幹細胞増殖促進剤
WO2024003418A1 (en) 2022-07-01 2024-01-04 Universiteit Maastricht Improved downregulation of histone cytotoxicity by complex of negatively charged polysaccharide and protease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds

Also Published As

Publication number Publication date
GR3005040T3 (ko) 1993-05-24
PT89534B (pt) 2001-05-31
ATE74273T1 (de) 1992-04-15
IE63528B1 (en) 1995-05-03
AU2885589A (en) 1989-08-03
CA1330299C (en) 1994-06-21
DK37789D0 (da) 1989-01-27
DK37789A (da) 1989-07-29
EP0326014A1 (en) 1989-08-02
JP2739050B2 (ja) 1998-04-08
US5084273A (en) 1992-01-28
IE890269L (en) 1989-07-28
KR0127754B1 (ko) 1998-04-01
JPH01193229A (ja) 1989-08-03
AU607303B2 (en) 1991-02-28
DE68901098D1 (de) 1992-05-07
ES2039709T3 (es) 1993-10-01
EP0326014B1 (en) 1992-04-01
PT89534A (pt) 1989-10-04

Similar Documents

Publication Publication Date Title
KR890011606A (ko) 항응고제
DE3674941D1 (de) Ozonentkeimung von blut und blutprodukten.
DE3587941D1 (de) Gerät zur vorläufigen reperfusionsbehandlung von herzanfallsymptomen.
DK0558529T3 (da) Farmaceutisk præparat til behandling af forlænget koagulationstid
KR890015742A (ko) 이병치료용 국소 제제
KR950701820A (ko) 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
KR890012659A (ko) 조산아의 뇌실내 출혈방지용 치료제
ATE59781T1 (de) Potenzierung von prazosin.
KR880009661A (ko) 궤양성 대장염치료를 위한 사람의 혈액응고인자 xiii의 용도
DE59003020D1 (de) Piroxicam enthaltende pharmazeutische Zusammensetzung zur topischen Anwendung.
KR890003373A (ko) 수면장애 및 우울증 치료에 화합물의 이용
KR910021244A (ko) 당뇨병성 괴저 치료제
KR900012622A (ko) 피부질환치료 조성물
KR870007667A (ko) 떡의 부패 방지법
KR880000094A (ko) 위염치료제
KR910700061A (ko) 인터로이킨-1β의 안정화 조성물
KR890012643A (ko) 루신(Leucine)에 의한 생체에너지원 대체 용도
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도
KR880012237A (ko) 트롬빈 제제의 제조방법
AU5199286A (en) New use of 1,4-dihydropyridine derivatives
KR910002464A (ko) 무좀 치료제
KR890003367A (ko) 심장질환 치료용 조성물
KR900015747A (ko) 간장관련 질병 치료제의 제조방법
KR900002770A (ko) 산화형 글루타티온 점안제
KR890001549A (ko) 위염 치료제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20041012

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee